• Publications
  • Influence
The blockade of immune checkpoints in cancer immunotherapy
  • D. Pardoll
  • Biology, Medicine
  • Nature Reviews Cancer
  • 22 March 2012
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired intoExpand
  • 7,085
  • 407
  • PDF
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
BACKGROUND Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibodyExpand
  • 8,514
  • 341
  • PDF
STATs in cancer inflammation and immunity: a leading role for STAT3
Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in determining whether immuneExpand
  • 2,903
  • 185
  • PDF
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
BACKGROUND Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system.Expand
  • 5,440
  • 178
  • PDF
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Activated tumor-infiltrating lymphocytes may induce B7-H1 on melanocytes, which suggests adaptive resistance to antitumor immunity. The Great Escape In the movie The Great Escape, “problem” prisonersExpand
  • 1,575
  • 85
Immune checkpoint blockade: a common denominator approach to cancer therapy.
The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance andExpand
  • 1,948
  • 82
  • PDF
Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Immune cells in the tumour microenvironment not only fail to mount an effective anti-tumour immune response, but also interact intimately with the transformed cells to promote oncogenesis actively.Expand
  • 1,445
  • 78
  • PDF
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
PURPOSE Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability ofExpand
  • 2,152
  • 69
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase 2 clinicalExpand
  • 2,220
  • 68
  • PDF
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis.Expand
  • 1,069
  • 64